21:41 , Sep 29, 2017 |  BC Week In Review  |  Financial News

Engage, Integra raise venture financings

Epilepsy play Engage Therapeutics Inc. (Summit, N.J.) and life science investment company Integra Holdings (Jerusalem, Israel) announced venture financings, raising nearly $50 million. Engage raised $23 million on Sept. 27 in a series A round...
00:04 , Sep 28, 2017 |  BC Extra  |  Financial News

Venture roundup: Engage, Integra

On Wednesday, epilepsy play Engage Therapeutics Inc. (Summit, N.J.) and life science investment company Integra Holdings (Jerusalem, Israel) announced venture financings, raising nearly $50 million. Engage raised $23 million in a series A round led...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

Ladostigil: Interim Phase IIb data

Avraham said interim data from a double-blind, international Phase IIb trial in 210 MCI patients showed that once-daily 10 mg oral ladostigil for up to 2 years led to a positive trend on the primary...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Financial News

Avraham Pharmaceuticals completes venture financing

Avraham Pharmaceuticals Ltd. , Yavneh, Israel   Business: Neurology   Date completed: 2014-09-17   Type: Venture financing   Raised: $4.5 million   Investors: Yissum Ltd.; Pontifax; Clal Biotechnology Industries; Technion Research and Development Foundation; and...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

Ladostigil: Phase IIb ongoing

Avraham said an independent expert committee concluded there were no serious or unexpected adverse events preventing continuation of a double-blind, placebo-controlled, international Phase IIb trial of ladostigil based on safety data from patients who have...
08:00 , Feb 25, 2013 |  BC Week In Review  |  Financial News

Avraham Pharmaceuticals completes venture financing

Avraham Pharmaceuticals Ltd. , Yavneh, Israel   Business: Neurology   Date completed: 2/21/13   Type: Venture financing   Raised: $5.7 million   Investors: Yissum; Pontifax; Clal Biotechnology Industries; Technion Research and Development Foundation  ...
07:00 , May 28, 2012 |  BC Week In Review  |  Clinical News

Ladostigil: Completed Phase II enrollment

Avraham completed enrollment of about 200 patients in a double-blind, placebo-controlled, European Phase II trial evaluating 80 mg oral ladostigil twice daily for 26 weeks in patients with mild to moderate AD. Avraham has an...
07:00 , May 28, 2012 |  BC Week In Review  |  Clinical News

Ladostigil: Phase II started

Avraham began a 36-month, double-blind, placebo-controlled, international Phase II trial to evaluate 10 mg oral ladostigil daily in at least 200 patients. Avraham has an exclusive, worldwide license to develop and commercialize ladostigil to treat...
07:00 , May 28, 2012 |  BC Week In Review  |  Company News

Avraham Pharmaceuticals management update

Avraham Pharmaceuticals Ltd. , Tel Aviv, Israel   Business: Neurology   Transitioned: Yona Geffen to CEO from SVP of clinical affairs and COO  ...
07:00 , May 28, 2012 |  BC Week In Review  |  Company News

Avraham Pharmaceuticals board of directors update

Avraham Pharmaceuticals Ltd. , Tel Aviv, Israel   Business: Neurology   Appointed: Yaacov Michlin as chairman, he is CEO of the Yissum Research Development Company Ltd. tech transfer arm of the Hebrew University of Jerusalem...